{
    "clinical_study": {
        "@rank": "52018", 
        "arm_group": [
            {
                "arm_group_label": "Subjects previously received and are receiving Ranibizumab", 
                "description": "150 Subjects who have previously and continue to receive Ranibizumab 0.5 mg."
            }, 
            {
                "arm_group_label": "Subjects previously received and are receiving Aflibercept", 
                "description": "150 Subjects who have previously and continue to receive Aflibercept 2 mg."
            }
        ], 
        "brief_summary": {
            "textblock": "This open-label, Phase IV prospective, observational study will evaluate patients, who have\n      been diagnosed with Neovascular Age-Related Macular Degeneration and have previously\n      received either a standard intravitreal injection of ranibizumab or aflibercept, in order to\n      get and compare information regarding post-injection inflammatory (irritation in the eye)2-3\n      days post-injection.\n\n      Additionally, patients will be evaluated for visual acuity and pain 2-3 days post-injection.\n\n      THIS IS AN OBSERVATION STUDY AND NOT AN INTERVENTIONAL STUDY AS TO ENTER THIS STUDY SUBJECTS\n      WILL HAVE HAD TO RECEIVED EITHER RANIBIZUMAB 0.5 MG OR AFIBERCEPT 2MG PRIOR TO ENTERING THE\n      STUDY AND SIGNING CONSENT.  THIS STUDY IS TO OBSERVE THE SUBJECT POST-INJECTION RECEIVED\n      BEFORE ENTERING THIS STUDY."
        }, 
        "brief_title": "Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients", 
        "condition": "Age Related Macular Degeneration", 
        "condition_browse": {
            "mesh_term": [
                "Inflammation", 
                "Macular Degeneration"
            ]
        }, 
        "detailed_description": {
            "textblock": "Patients, age 65 to 90, with Neovascular Age-Related Macular Degeneration who present for\n      treatment with intravitreal ranibizumab or aflibercept will be selected in this study.  300\n      subjects from one site in the United States will be enrolled."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Ability to provide written informed consent and comply with study assessments for the\n             full duration of the study\n\n          -  Age 65-90 years\n\n          -  Diagnosis or Neovascular Age-Related Macular Degeneration who present for treatment\n             with intravitreal ranibizumab or aflibercept\n\n        Exclusion Criteria:\n\n          -  Previous intraocular inflammation\n\n          -  Treatment with systemic anti-inflammatory agents\n\n          -  Known systemic autoimmune diseases\n\n          -  Treatment with intraocular steroids in the past 3 months\n\n          -  History of intraocular surgery in the past 3 months\n\n          -  Age greater than 90 years\n\n          -  Patients who were switched between either therapies in the past 3 months"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "90 Years", 
            "minimum_age": "65 Years", 
            "sampling_method": "Probability Sample", 
            "study_pop": {
                "textblock": "Private practice patients referred to retinal specialist for treatment of Neovascular\n        Age-Related Macular Degeneration"
            }
        }, 
        "enrollment": {
            "#text": "300", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "November 11, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01991730", 
            "org_study_id": "NJRetina-ML28942", 
            "secondary_id": "NJRetina Observational ML28942"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Macular", 
            "Degeneration", 
            "Age related"
        ], 
        "lastchanged_date": "November 21, 2013", 
        "location": {
            "contact": {
                "email": "rothretina@gmail.com", 
                "last_name": "Daniel Roth, MD", 
                "phone": "732-220-1600"
            }, 
            "facility": {
                "address": {
                    "city": "New Brunswick", 
                    "country": "United States", 
                    "state": "New Jersey", 
                    "zip": "08901"
                }, 
                "name": "NJ Retina"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Intravitreal Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients", 
        "other_outcome": {
            "description": "Pain will be measured on a standardized pain scale; VFQ-25 and a 0-10 numeric pain scale.", 
            "measure": "To evaluate patient's pain post-injection", 
            "safety_issue": "No", 
            "time_frame": "2-3 days post-injection"
        }, 
        "overall_contact": {
            "email": "rothretina@gmail.com", 
            "last_name": "Daniel Roth, MD", 
            "phone": "732-220-1600"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "All eyes will be evaluated 2-3 days after injection and graded in terms of (a) aqueous cells, graded subjectively on a scale of 0-4, (b) aqueous flare, graded subjectively on a scale 0-4, (c) aqueous flare graded objectively with the FM-600 Kowa flare meter and (d) vitreous haze, graded subjectively on a scale of 0-4.", 
            "measure": "To evaluate post-intravitreal injection inflammatory response in patients receiving either ranibizumab or aflibercept.", 
            "safety_issue": "Yes", 
            "time_frame": "Study eyes will be evaluated 2-3 days after injection"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01991730"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Best corrected visual acuity will be assessed by the number of letters read correctly on the ETDRS eye chart at a starting test distance of 4 meters.", 
            "measure": "To evaluate patients 2-3 days post-injection for best corrected visual acuity", 
            "safety_issue": "No", 
            "time_frame": "2-3 days post-injection"
        }, 
        "source": "NJ Retina", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "NJ Retina", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "November 2013"
    }
}